Catalyst Forum: Life Sciences
November 17, 2020 | 1:00 PM - 5:00 PM ET
Nobel Laureate Michael Houghton
PhD, DSc Hon, Canada Excellence Research Chair in Virology and Li Ka Shing Professor of Virology at the University of Alberta; Director of the Li Ka Shing Applied Virology Institute
Managing Partner, Gurnet Point Capital, former CEO and Chairman of the Board, Sanofi
President & Chief Executive Officer, Repare Therapeutics
Development Producer at Science Friday
The second edition of the Catalyst Forum: Life Sciences was another opportunity to bring together members of the CENE and its network of successful Boston-based Canadians for a half day of discovery, collisions, networking and learning.
This virtual program included insights into new developments in Canadian life sciences, input from the CENE's Life Sciences Leadership Council and feature a showcase of emerging growth Canadian life sciences companies.
1:00 - 1:30 Welcome and Introductions
Ty J. Shattuck, Chief Executive Officer at McMaster Innovation Park
Gordon McCauley, President & CEO, adMare Bioinnovations
Anny Bedard, President, ABio Consulting | Executive Committee, CENE Life Sciences Leadership Council
1:30 - 2:15 Harvesting the North: Value Creation Among Canadian Biotech Companies
Over the past few years, Canadian biotech innovation has come out of its “quiet period” and is ripe for investment and return. In 2019, we saw Canada’s largest acquisition ($1 Billion acquisition of Clementia) and this year, we had a top NASDAQ IPO (Repare Therapeutics). As more venture capital and large companies look North for innovation, the reputation and valuation of Canadian biotech is on the rise.
Christopher Viehbacher, Managing Partner, Gurnet Point Capital, former CEO and Member of the Board of Directors of Sanofi
2:30 - 3:30 Showcase Session
Join this interactive session for a presentation of some of Canada’s leading emerging growth life sciences companies.
Adapsyn, a chemical bioinformatics company that discovers and develops novel small molecule therapeutics. Adapsyn’s platform analyses metabolomic and genomic data from bacteria to identify, isolate, characterize, and assay novel drug-like molecules.
CCRM, a global public-private partnership headquartered in Canada, is funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners. It supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.
Neuraura, founded to improve the lives of billions of people suffering from neurological, psychiatric and sensory conditions through the development of fully implantable medical devices with closed-loop recording and stimulation, also known as neuromodulation.
Sonic Incytes, a medical technology company focused on developing quantitative ultrasound first targeting the rapidly growing global fatty liver pandemic. Sonic Incytes’s flagship product, Velacur, is FDA 510(k) cleared and the company is actively adding customers in the United States.
Steadiwear, their the Steadi-One, is a lightweight, compact and battery-free glove that responsively stabilizes the wrist in Parkinson’s disease and Essential Tremor patients. With the essential tremor and Parkinson’s diseases affecting 3% of the population, Steadiwear is addressing the needs of 230 million individuals worldwide and is targeting a $4.8 billion market in the U.S. alone.
VoxNeuro, VoxNeuro’s Cognitive Health Assessment™ is the first assessment in the world that reliably measures all core brain functions, helping medical professionals make informed treatment decisions with actionable data about brain health.
Zucara Therapeutics, Zucara Therapeutics is developing ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels) in people with Type 1 and Type 2 diabetes using insulin therapy. ZT-01 restores glucagon secretion to prevent hypoglycemia, which could dramatically change diabetes disease management and improve both patient health and quality of life.
KisoJi, KisoJi is a privately-held next-generation antibody company developing multi-specific antibodies to improve outcomes in oncology. Using next generation sequencing, machine learning and transgenic technologies, KisoJi has developed a powerful new multi-specific antibody discovery platform. Our lead product is a tri-specific antibody (D2 x PD1 x CD3) that targets: the dopamine receptor, PD1 and CD3, which provide tumor targeting, checkpoint inhibition, and T-cell recruitment, respectively. Other antibodies targeting checkpoint inhibitors, cancer metabolism, immune and tumor associated antigens are incorporated as modules in our multi-specific antibody pipeline.
Vinit Nijhawan, Managing Director, MassVentures
3:45 - 4:30 Fireside Chat with Nobel Laureate Michael Houghton, PhD, DSc Hon
Science Friday’s Elah Feder joins 2020 Nobel Laureate Michael Houghton, PhD, DSc Hon, Canada Excellence Research Chair in Virology and Li Ka Shing Professor of Virology at the University of Alberta; Director of the Li Ka Shing Applied Virology Institute, for a discussion.
Thanks to the sponsors of the Catalyst Forum:
Thanks to our Community Supporters: